1. Scrip

Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals

 
• By Jessica Merrill

Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.

Tepezza's relaunch is a commercial success • Source: Alamy

Horizon Therapeutics plc's star drug Tepezza (teprotumumab) is fully back up and running after a manufacturing supply issue kept it off the market in early 2021. Revenue for the thyroid eye disease (TED) drug is now expected to exceed $1.55bn in full year sales, the company reported on 4 August.

Tepezza generated $453.3m in revenue in the second quarter, exceeding expectations, after the drug was returned to the market in April. The US Food and Drug Administration approved new manufacturing for Tepezza in March after the company's initial contract manufacturer was redirected by the US government to prioritize COVID-19 vaccine production. (Also see "With Return Of Tepezza Supply, Horizon Is Ready To Get Back To Business" - Scrip, 31 March, 2021

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.